Clinical Trial Update: Efficacy of Topical Cyclosporine 0.05% in the Prevention of Ocular Surface Inflammation Secondary to Pterygia [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating topical cyclosporine 0.05% for preventing ocular surface inflammation associated with pterygium; study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pterygium

Drugs mentioned

• Cyclosporine 0.05% topical solution (cyclosporine)

Snippet

Sponsor: Innovative Medical | Conditions: Pterygia | Phase 4 | Status: COMPLETED